As of November 6, 2026, Aligos Therapeutics, Inc. is a publicly traded company (Nasdaq: ALGS). The largest holder reporting an active stake on Schedule 13D is Lawrence M. Blatt, the executive officer and a director, at 5.6%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Sio Capital Management, LLC (5.46%) (Schedule 13D, June 24, 2026).
Is this your company?
About to sign with, pay or invest in Aligos Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Aligos Therapeutics, Inc. a real, registered company?
- Aligos Therapeutics, Inc. files with the SEC under CIK 1799448 (its SEC filings).
- Its shares are listed under the ticker ALGS on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Aligos Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Lawrence M. Blatt (filed 2026-06-24).
Who are Aligos Therapeutics, Inc.'s owners and officers?
Aligos Therapeutics, Inc.: incorporated in Delaware; business address in South San Francisco, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13D, 2026-06-24).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-02-28)
- : Executive Officer (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
- : Executive Officer (Form D, 2025-02-28)
- : Executive Officer (Form D, 2025-02-28)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D, 2026-06-24 | Lawrence M. Blatt | 5.6% |
| Schedule 13G/A, 2026-05-15 | Woodline Partners LP | 4.4% |
| Schedule 13G, 2026-05-15 | Lawrence M. Blatt | 5.1% |
| Schedule 13G/A, 2026-02-17 | Woodline Partners LP | 5.4% |
| Schedule 13G/A, 2026-02-11 | Sio Capital Management, LLC | 5.46% |
| Schedule 13G/A, 2025-11-14 | Woodline Partners LP | 8.7% |
| Schedule 13G/A, 2025-08-14 | Woodline Partners LP | 9.8% |
| Schedule 13G, 2025-08-13 | Sio Capital Management, LLC | 5.49% |
| Schedule 13G/A, 2025-08-12 | Adage Capital Management, L.P. | 3.9% |
Questions about who owns Aligos Therapeutics, Inc.
Who owns Aligos Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Aligos Therapeutics, Inc.: Lawrence M. Blatt (5.6%, Schedule 13D, filed 2026-06-24) and Sio Capital Management, LLC (5.46%, Schedule 13G/A, filed 2026-02-11).
Who are the largest shareholders of Aligos Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Aligos Therapeutics, Inc. on this page are Lawrence M. Blatt (5.6%) and Sio Capital Management, LLC (5.46%).
When did Lawrence M. Blatt buy into Aligos Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lawrence M. Blatt on this page is the Schedule 13G, filed 2026-05-15, reporting 5.1%; its latest, Schedule 13D filed 2026-06-24, reports 5.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Aligos Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aligos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aligos Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
How much has Aligos Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-02-28 | $105M | $105M |
| Form D, 2023-11-07 | $92.15M | $92.15M |
Keep reading
More on Aligos Therapeutics, Inc. and the records around it.
Aligos Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Jun 2026
Companies that share a holder
- Sio Capital Management, LLC also filed stake reports on 9 other companies: Enveric Biosciences, Inc. (Nov 2026), Adagio Medical Holdings, Inc. (Jul 2026), PMV Pharmaceuticals, Inc. (Jul 2026)
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Adage Capital Management, L.P. also filed stake reports on 136 other companies: ACP Holdings Acquisition Corp. (Aug 2026), AmperCap Acquisition Company (Aug 2026), Aura Biosciences, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/aligos-therapeutics